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Temporal relationship between renal cyst development, hypertension and
cardiac hypertrophy in a new rat model of autosomal recessive polycystic
kidney disease
Abstract

Background/Methods: We have examined the hypothesis that cyst formation is key in the pathogenesis of
cardiovascular disease in a Lewis polycystic kidney (LPK) model of autosomal-recessive polycystic kidney
disease (ARPKD), by determining the relationship between cyst development and indices of renal function
and cardiovascular disease. Results: In the LPK (n = 35), cysts appear at week 3 (1.1 ± 0.1 mm) increasing to
week 24 (2.8 ± 2 mm). Immunostaining for nephron-specific segments indicate cysts develop predominantly
from the collecting duct. Cyst formation preceded hypertension (160 ± 22 vs. Lewis control 105 ± 20 mm Hg
systolic blood pressure (BP), n = 12) at week 6, elevated creatinine (109 ± 63 vs. 59 ± 6 μmol/l, n = 16) and
cardiac mass (0.7 vs. 0.4% bodyweight, n = 15) at week 12, and left ventricular hypertrophy (2,898 ± 207 vs.
1,808 ± 192 μm, n = 14) at week 24 (all p ≤ 0.05). Plasma-renin activity and angiotensin II were reduced in
10- to 12-week LPK (2.2 ± 2.9 vs. Lewis 11.9 ± 4.9 ng/ml/h, and 25.0 ± 19.1 vs. 94.9 ± 64.4 pg/ml,
respectively, n = 26, p ≤ 0.05). Ganglionic blockade (hexamethonium 3.3 mg/kg) significantly reduced mean
BP in the LPK (52 vs. Lewis 4%, n = 9, p ≤ 0.05). Conclusion: Cyst formation is a key event in the genesis of
hypertension while the sympathetic nervous system is important in the maintenance of hypertension in this
model of ARPKD.
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Abstract
Background/Methods: We have examined the hypothesis
that cyst formation is key in the pathogenesis of cardiovascular disease in a Lewis polycystic kidney (LPK) model of autosomal-recessive polycystic kidney disease (ARPKD), by determining the relationship between cyst development and
indices of renal function and cardiovascular disease. Results:
In the LPK (n = 35), cysts appear at week 3 (1.1 8 0.1 mm) increasing to week 24 (2.8 8 2 mm). Immunostaining for nephron-specific segments indicate cysts develop predominantly from the collecting duct. Cyst formation preceded
hypertension (160 8 22 vs. Lewis control 105 8 20 mm Hg
systolic blood pressure (BP), n = 12) at week 6, elevated creatinine (109 8 63 vs. 59 8 6 mol/l, n = 16) and cardiac mass
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(0.7 vs. 0.4% bodyweight, n = 15) at week 12, and left ventricular hypertrophy (2,898 8 207 vs. 1,808 8 192 m, n =
14) at week 24 (all p ^ 0.05). Plasma-renin activity and angiotensin II were reduced in 10- to 12-week LPK (2.2 8 2.9 vs.
Lewis 11.9 8 4.9 ng/ml/h, and 25.0 8 19.1 vs. 94.9 8 64.4
pg/ml, respectively, n = 26, p ^ 0.05). Ganglionic blockade
(hexamethonium 3.3 mg/kg) significantly reduced mean BP
in the LPK (52 vs. Lewis 4%, n = 9, p ^ 0.05). Conclusion: Cyst
formation is a key event in the genesis of hypertension while
the sympathetic nervous system is important in the maintenance of hypertension in this model of ARPKD.
Copyright © 2007 S. Karger AG, Basel

Introduction

Hypertension is a common and early clinical feature
of both autosomal-dominant and -recessive variants of
polycystic kidney disease (PKD) [1, 2] and has a major
role in the development of left ventricular hypertrophy
(LVH) as well as the progression to end-stage renal failure
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[3, 4]. An understanding of the pathogenesis and progression of hypertension is therefore critical to identifying
key interventions and limiting morbidity in PKD.
The mechanisms of hypertension in PKD are not well
defined and it has been hypothesised that one of the initial precipitants is the development of gross abnormalities in renal structure due to cyst formation causing local
tissue ischaemia and the activation of a variety of mediators including the renin-angiotensin-aldosterone system
(RAAS), vasoactive peptides and sympathetic nervous
system (SNS) [5, 6]. This would suggest that hypertension
occurs simultaneously with cyst formation, and precedes
development of LVH. Indeed, this is consistent with clinical experience and cross-sectional studies of humans
with PKD [5, 7]. The prospective evaluation of this hypothesis in humans is difficult and requires examination
in animal models. In that regard, a number of mouse and
rat models of PKD are described. In the rat, all known
models are the result of spontaneous genetic mutations,
while in mice many have been engineered through chemical induction or insertional mutagenesis including targeted mutagenesis of human PKD orthologs [8, for review]. However, to date these models of PKD including
the heterozygous Han:SPRD PKD and autosomal-recessive PKD (ARPKD) wpk animals show either no or only
mild-to-moderate elevations in blood pressure [9–11] and
no evidence of progressive cardiovascular disease. Furthermore, genetically engineered mouse models may
have specific defects in the cardiovascular system, which
may make interpretation complicated [12].
We have examined the overriding hypothesis that cystogenesis is a key event in the pathogenesis of cardiovascular disease in PKD by undertaking a temporal analysis of
renal morphology, indices of renal function, blood pressure and cardiac hypertrophy in a new Lewis rat model of
PKD (LPK). In order to gain an appreciation of the mechanisms driving hypertension, we have also examined the
respective contributions of RAAS and SNS. Preliminary
data regarding the LPK model [13] indicates the key trait
of marked hypertension from an early age, with inheritance features suggestive of ARPKD. Classically, the cystic
lesions in ARPKD arise predominantly from the collecting
duct [8] whereas in autosomal-dominant PKD (ADPKD),
recent data suggest cysts arise predominantly from the distal nephron [14, 15]. Therefore, in order to determine the
site of origin of cysts in the LPK model, we have performed
immunohistochemistry to: (1) determine the nephronsegment origin of the cysts, and (2) assess the degree of
tubulointerstitial damage, a common histological accompaniment of PKD and predictor of progression.
130
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Materials and Methods
Animals
All experiments were carried out with the approval of the Animal Ethics committees of the respective institutions. Lewis rats
with PKD arising as a spontaneous mutation were identified at
the Animal Resources Centre, Perth Australia (2002) in a LEW/
SsNArc (Lewis) inbred strain originally received from the Department of Health and Human Services, National Institute of
Health, USA (1990). The Lewis animals with PKD (LPK) were
inbred by brother/sister matings of affected littermates and maintained as an inbred colony. Standard inbred Lewis rats (LEW/
CrlBR) bred at the Animal Resources Centre were used as a control strain. The LPK females produced one litter of 8–12 pups at
12–15 weeks of age and did not reproduce again. Animals did not
survive beyond 26 weeks of age.
In order to characterise the mode of inheritance, mating experiments were performed. LPK ! LPK crossings yielded offspring which all exhibited renal cysts (50 pairs, 345 [100%] polycystic progeny). Brown Norway (BN) ! LPK crossings (F1)
yielded offspring with no detectable cysts (3 pairs, 3 litters, 18
progeny). For the F1 ! F1 crossings (F2; 16 pairs, 16 litters, 152
offspring), 38 developed cystic kidneys (25%, 2 value = 0.00,
p ! 0.05). This frequency of PKD in F2 animals supports an autosomal recessive pattern of Mendelian inheritance for a single
gene mutation.
Experimental Design and Assessment of Blood Pressure
Whole body and tissue-specific measurements were collected
from LPK and Lewis rats at the time points of 3, 6, 12, 16 and 24
weeks of age. At each time point, a minimum of 6 rats (3 female,
3 male) of each strain was used (n = 36 LPK rats, 31 Lewis rats).
Prior to CO2 euthanasia, body weight and tail-cuff blood pressure
measurements were made (average of 3 measurements after acclimatization; NIBP controller, ADI Instruments, Castle Hill,
NSW, Australia) and voided urine samples collected. Urine was
not collected from 3-week-old animals. Immediately following
euthanasia, blood was collected by cardiac puncture and wet
kidney, heart, pancreas and liver weight recorded. Three other
additional groups of animals were used. A group of mixed sex 1week-old LPK and Lewis rats (n = 6 each strain, total 12 rats) were
euthanised and renal tissue collected and processed for morphometric quantification. A group of mixed sex 10- to 12-week-old
LPK and Lewis rats (n = 18 and 8, respectively, total 26 rats) were
used for collection of blood for plasma-renin activity (PRA), angiotensin II (Ang II) and aldosterone analysis. After stunning and
decapitation, blood was collected in chilled tubes containing Na2
EDTA, the plasma collected and then stored at –80 ° C until further hormonal analysis. Additional blood was collected for serum
urea and creatinine levels. A final group of mixed sex 16-week-old
LPK and Lewis rats (n = 4 Lewis, 5 LPK, total 9 animals) were used
for ganglionic blockade. Animals were anaesthetised with urethane (Sigma-Aldrich, Mo., USA; 1.2 g/kg i.p.) and a cannula was
placed in the femoral artery. The cannula was connected via a
bridge amplifier to a Powerlab (AD Instruments) data system.
The ganglionic blocking agent hexamethonium bromide (Sigma)
was administered subcutaneously (3.3 mg/kg) during continuous
measurement of arterial pressure and heart rate. Preliminary
studies indicated this dosage as one that produced consistent and
tolerated effects in the LPK. Systolic pressure, diastolic pressure,
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Table 1. Primary and secondary antibodies used for kidney immunohistochemistry

Primary antibodies

Dilution and
source

Secondary
antibodies

Antibody
target/marker

Indicator

Monoclonal mouse -rat,
clone ED-1, IgG1 Isotype

1:400, Serotec, UK

biotinylated rabbit
-mouse IgG1

monocytes and macrophages/inflammation

tubulointerstitial
damage

Monoclonal mouse -smooth
muscle actin (SMA) clone1A4,
IgG2a Isotype

1:4,000; SigmaAldrich, Sydney,
Australia

biotinylated rabbit
-mouse IgG2a

interstitial myofibroblast
accumulation

tubulointerstitial
damage

Monoclonal mouse -proliferating cell nuclear antigen (PCNA),
clone PC10, IgG2a Isotype

1:100; Dako, Carpinteria, Calif., USA

biotinylated rabbit
-mouse IgG2a

tubular epithelial cell
(TEC) proliferation/
inflammation

tubulointerstitial
damage

Monoclonal mouse -vimentin,
clone V9, IgG1 Isotype

1:100; Dako, Sydney,
Australia

biotinylated rabbit
-mouse IgG1

intermediate filament
protein/dedifferentiated
epithelia

tubulointerstitial
damage

Monoclonal mouse -rat
Aquaporin-1 (AQP1), IgG2b
Isotype

1:100; Abcam, Cambridge Science Park,
Cambridge, UK

biotinylated goat
-mouse immunoglobulins IgG

proximal convoluted
tubule (PCT) and thin
descending limb of
Henle’s loop (DL)

cyst origin

Polyclonal sheep -TammHorsfall glycoprotein (THG)
IgG Isotype

1:200; Chemicon,
Boronia, Vic., Australia

biotinylated rabbit
-sheep IgG

thick ascending limb (AL)
and distal convoluted
tubule (DCT)

cyst origin

Polyclonal rabbit -rat Aquaporin-2 (AQP2) IgG Isotype

1:100; Abcam

biotinylated goat
-rabbit IgG

cortical and medullary
collecting ducts (CD)

cyst origin

mean arterial pressure (MAP) and heart rate were continuously
measured until reaching a steady level within 3–5 min of drug
administration.
Clinical Biochemistry and Haematology
Full biochemical profiles were performed on animals at weeks
6, 12 and 24. At 3 and 16 weeks, only serum urea and creatinine
were determined. Serum creatinine, urea, protein, bilirubin, alkaline phosphatase (ALP), aspartate amino transferase (AST) and
alanine amino transferase (ALT) were measured using a Rx Daytona analyser (Randox Laboratories, Antrum, UK). PRA and Ang
II levels were determined by radioimmunoassay (ProSearch International Australia, Malvern, Vic., Australia). Plasma aldosterone concentrations were ascertained using a commercially available radioimmunoassay kit (Count a Coat, Diagnostic Products
Corporation, California, USA, undertaken by ProSearch International Australia). Micro haematocrit tubes were used to determine packed cell volume (PCV). Urine specific gravity (USG) was
measured using a refractometer and urine protein to creatinine
ratio determined using a Cobas Mira analyser (Roche Diagnostics, Schweiz, AG).
Tissue Histology
The heart, liver and pancreas were placed into 4% formalin
prior to embedding in paraffin wax for histological analysis. Liver, pancreas and a mid-ventricle section of the heart were stained
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with haematoxylin and eosin (HE) and examined by standard
light microscopy. Coronal sections of the kidney were fixed in
methyl Carnoy’s solution or 4% formalin and after paraffin embedding, 4-m-thick sections were stained with periodic acidSchiff (PAS) for cyst morphometric analysis and Gomori’s trichrome for histological assessment of collagen deposition.
Immunohistochemistry of the Kidney
To assess the degree of tubulointerstitial damage, and origin
of cyst formation, immunohistochemistry using the primary and
secondary antibodies as indicated in table 1 was performed. For
tubulointerstitial damage, markers for interstitial inflammation
(macrophage/monocytes, detected by ED-1 antigen), interstitial
myofibroblast accumulation (-smooth muscle actin, SMA), tubular dedifferentiation (vimentin, an intermediate filament protein expressed in dedifferentiated but not normal epithelia) and
tubular epithelial cell (TEC) proliferation (proliferating cell nuclear antigen, PCNA) were used. For determination of cyst origin,
the primary antibodies against the following specific nephron
segments were used: aquaporin-1 (AQP1) which is a marker for
the proximal convoluted tubule and the thin descending limb of
Henle’s loop [16]; Tamm-Horsfall glycoprotein (THG) which is
expressed by the thick ascending limb and distal convoluted tubule [17] and aquaporin-2 (AQP2), whose expression is localised
to the apical domains in the principal cells of the cortical and
medullary collecting ducts [18, 19].
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Primary antibodies were incubated at 4 ° C overnight, followed
by biotinylated species-specific secondary antibodies. All secondary antibodies were used at a dilution of 1: 400 and were from
Zymed Laboratories (San Francisco, Calif., USA) except for the
biotinylated goat anti-mouse immunoglobulins IgG (1: 400, Dako,
Botany, NSW, Australia). Sections were incubated for 30 min with
secondary antibodies. All primary and secondary antibodies
were diluted using phosphate buffered saline (PBS; pH 7.4) with
1% bovine serum albumin (BSA) and 1% Tween-20. Immunoreactivity was visualised with Vectastain Elite ABC  reagent (Vector Laboratories, Burlingame, Calif., USA) and the chromogen
diaminobenzidine (DAB; Sigma-Aldrich). Methyl-green 2% was
used for counterstaining followed by dehydration and application
of cover slips using Histomount (Invitrogen Corporation, Carlsbad, Calif., USA).
Morphometric Quantification of the Kidney
Sections were viewed with a microscope and the images were
digitalized using a video camera (BX51/ DP11; Olympus, Perth,
WA, Australia) linked to image analysis software (Optimas Image
Analysis, Version 5.2; Optimus Corp., Bothell, Wash., USA). A
uniformly random cluster method was used to determine microscopic fields for evaluation [20].
To assess cyst formation, cross-sectional diameter of individual cortical cysts was measured using line morphometry, with
diameter defined as the length of a straight line joining two points
on the cyst circumference. Subjectively, the greatest length possible between two points was taken and the largest cysts within
mid-cortical fields assessed. Mean average diameter for each section was determined.
Tubulointerstitial fibrosis was evaluated by quantitative image
analysis for percentage area occupied by positive staining for
interstitial -SMA in five mid-cortical fields. Magnification
!200.
Interstitial collagen deposition (Trichrome blue) was assessed
semiquantitatively from 0 to 4: 0, absent; 1, ! 25% of or deposition
of interstitial collagen (! 25%); 2, 25–50% of or deposition of interstitial collagen (25–50%); 3, 51–75% of or deposition of interstitial collagen (50–75%), and 4, 76–100% of deposition of interstitial collagen (175%). An average grade was established for each
section to determine a mean grade for each time point. Five medullary and five cortical fields from each animal were evaluated
(magnification !200, graticule 0.5 mm2).
For tubulointerstitial inflammation, ED-1-positive and
PCNA-positive interstitial cells were quantified in five midcortical fields measured at !200. The number of positive cells in each
field was counted and an average count was generated for each
section. Mean cell counts for each time point were established
(cells per mm2).
For semi-quantitative analysis of tubular vimentin five cortical fields from each animal were examined at !200 magnification and graded using a score as for collagen deposition. A tubule
was defined as positive for vimentin if it contained 6 one immunoreactive tubular epithelial cell.
Morphometric Quantification of the Heart
A composite image of the heart was taken using a light microscope (LEICA DMBRE, Wetzlar, Germany) and digital camera
(NIKON DXM1200F, Nikon Corporation, Kawasaki, Kanagawa,
Japan). The assessment of the thickness (m) of the right ven-
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tricular free wall, interventricular septum and left ventricular
free wall were determined using Image ProPlus image analysis
software (version 4.5.1.29, Media Cybernetics, LP, Md., USA).
Statistical Analyses
Results are presented as means 8 SD of combined male and
female results unless otherwise stated. All analysis was conducted
using the statistical package Statistical Package for the Social Sciences (SPSS; Chicago, Ill., USA). Analysis was performed using a
univariate general linear model against the fixed factors of age,
strain and sex. Significance was set at p ^ 0.05 and the adjusted
R 2 (relative predictive powers of the model adjusted for degrees of
freedom) provided. For tissue weights, data was converted to percentage body weight. Unless otherwise stated, data was not influenced by blood pressure when entered as a covariate in the model.
Level of statistical significance for the effect of strain is provided,
and if present, age/strain and/or sex interactions. Results of the
univariate analysis drove the Post Hoc analysis, performed using
Tukey test (p ^ 0.05). The correlation for aldosterone and creatinine was determined in the LPK using a Pearson correlation with
a two-tailed test of significance, p ^ 0.05.

Results

General Features
The gross phenotype of LPK rats was characterised by
progressive nephromegaly (fig. 1a, b). Age, sex and strain
all had a significant effect on bodyweight (table 2). There
was no macroscopic or microscopic evidence of cyst formation in the liver or pancreas at any age (fig. 1c, d). The
weight of the liver was significantly associated with age
(proportionally smaller in younger animals) and was
only different between the strains at 6 weeks (less in the
LPK; table 2). The pancreas showed no significant differences at any age.
LPK Rats Develop Laboratory Abnormalities
Consistent with Progressive Kidney Failure
Serum urea was significantly elevated from 3 weeks in
LPK rats and serum creatinine by 12 weeks, and both increased with age (table 3). Sex had a significant effect on
the levels of urea and creatinine in the LPK animals, with
males showing overall higher levels of both markers but
there was no age/sex interaction (fig. 2). Urinalysis demonstrated isosthenuria in the LPK rats from week 12 onwards (table 3) and the urine protein: creatinine ratio increased significantly in the LPK animals from 16 weeks
of age onwards (table 3; p ^ 0.05). At 12 weeks of age,
protein (total and albumin) levels were significantly reduced in LPK animals when compared with the Lewis
(table 4 ; p ^ 0.05). Globulin levels were reduced in the
LPK at 24 weeks of age (table 4 ; p ^ 0.05). Bilirubin and
Phillips et al.

a

b

c

d

Fig. 1. Gross and microscopic tissue features. In-situ images of
kidneys from a 12-week-old Lewis control (a) and 12-week-old
LPK (b) rat. Figure illustrates the dramatic increase in size of the

kidneys in LPK (arrow is pointing to left kidney in both panels)
and their pale and nodular appearance. Figure also illustrates the

normal gross appearance of the liver in the LPK (*). c, d Light microscopy of histological sections of body tissues stained with HE.
c shows histologically normal liver tissue from a 24-week-old LPK
animal, while d shows histologically normal pancreas from a 12week-old animal LPK. c, d Scale bar = 200 m.

the hepatic enzymes ALT and AST did not vary between
the strains (table 4). ALP levels showed an age effect, being higher in younger animals, which was more pronounced in the Lewis (p ^ 0.05). The PCV was less in the
LPK group than age matched Lewis from week 12, and
continued to decrease with increasing age (table 4, p ^
0.05). The anaemia was characterised as normocytic and
normochromic.

In the group of animals tested for PRA, Ang II and aldosterone, PRA levels were significantly less in the LPK
when compared to Lewis at 10–12 weeks of age (2.2 8 2.9
vs. 11.7 8 4.9 ng/ml/h, Adj R 2 = 0.599, p ! 0.001, n = 26).
Angiotensin II levels were also significantly less in the
LPK (25.0 8 19.1 vs. Lewis 94.9 8 64.4 pg/ml, Adj R 2 =
0.646, p ! 0.001). Angiotensin II levels showed a sex/strain
interaction, due to significantly higher levels of Ang II in
the male Lewis animals (109.6 8 17.3 pg/ml, n = 4, p !
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Table 2. Body weight and tissue features in age-matched Lewis and LPK rats
Tissue

Body, g
Liver, % BW
Pancreas, % BW
Kidneys, % BW

3 weeks

6 weeks

12 weeks

16 weeks

24 weeks

(6)LEW

(6)LPK

(6)LEW

(6)LPK

(7)LEW

(8)LPK

(6)LEW

(6)LPK

(6)LEW

66811
4.780.4
0.480.1
1.380.1

4083
4.580.3
0.480.1
6.580.7

145821
5.480.3
0.480.1
1.280.05

160838
4.080.2
0.380.1
6.282.0

261875
4.280.5
0.380.1
0.980.1

210843
3.580.4
0.580.1
8.381.2

303858
4.380.5
0.380.1
0.980.1

248863
3.580.7
0.580.0
9.681.0

327886 237850
3.480.7 3.280.8
0.380.1 0.580.1
0.980. 2 9.283.5

Adjusted
R2 value

(8)LPK

0.96***
0.91***
0.71
0.90***

Data represent mean 8 SD of combined male and female data. Minimum number of animals in each group indicated by superscript associated with
age/strain column. Significance of strain effect: *** p ≤ 0.001.

Table 3. Biochemical and urological parameters in age-matched Lewis and LPK rats
Parameter

3 weeks
(6)LEW

Urea, mmol/l
Creatinine, mol/l
USG
Urine Pr:Cr ratio

6 weeks
(6)LPK

580.6
1382
5684
3084
1.04180.01 1.03980.0
–
–

(6)LEW

12 weeks
(8)LPK

580.3
1284
4582
64813
1.01580.01 1.02380.01
2.681.4
5.383.1

(8)LEW

16 weeks
(8)LPK

(6)LEW

781
34823
5986
109863
1.02980.02 1.01280.0
1.180.5
5.382.6

24 weeks
(6)LPK

(6)LEW

780.3
44818
4985
150870
1.01580.0 1.01180.0
2.181.0 19.2818.5

Adjusted
R2 value

(9)LPK

680.7
80821
5285
279870
1.03580.01 1.01380.0
1.681.2
31.8822.1

0.83***
0.87***
0.50**
0.50***

Data represent mean 8 SD of combined male and female data. Urine specific gravity (USG; isosthenuria range 1.008–1.012), protein:creatinine (Pr:Cr, protein units g/l, creatinine units mol/l; calculation (8,840) ! (urinary protein/urinary creatinine). Minimum number of animals in each group indicated by superscript associated with age/strain
column. Significance of strain effect: ** p ≤ 0.01; *** p ≤ 0.001.

Kidney Cysts Arise from the Distal Nephron at Week 3
Kidney weight in LPK rats progressively increased (table 2), with the surface becoming more irregular due to
cyst formation. Macroscopically, the reniform shape of

Fig. 2. Graphical representation of elevation in serum urea (a) and
creatinine (b) in male and female LPK animals. Serum urea levels

increased with age for both sexes, and while there was no significant difference between males and females at any time point,
overall there were significantly higher levels in the male rats (adjusted R 2 = 0.754, sex effect p = 0.033). This effect was more pronounced for serum creatinine (b ; adjusted R 2 = 0.838, sex effect
p ^ 0.001). * Significant difference between males and females at
that age, p ^ 0.05. Data are means 8 SD, n = 37.
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Female LPK

Male LPK

Serum urea (mmol/l)

120

a

100
80
60
40
20
0

3

6

12

16

300

200

100

0

b

24

*

400

Serum creatinine (µmol/l)

0.001). Plasma aldosterone levels were not significantly
different between the two groups (446.5 8 442.3 vs. Lewis 412.2 8 155.8 pg/ml), but there was a wide range in the
LPK results. This prompted a correlation analysis that
showed aldosterone levels in the LPK were positively correlated with creatinine (Pearson correlation co-efficient
0.607, p = 0.008, n = 18). Creatinine was significantly different between LPK and Lewis in this cohort (73.7 8 38.3
vs. 46.2 8 5.7 mol/l, respectively, p ^ 0.05).

3

6

12
Age (weeks)

Phillips et al.

16

24

Table 4. Biochemical and haematological parameters in age-matched Lewis and LPK rats

Parameter

6 weeks
(6)

6082
3681
2481
280.0
121840
2408110
530854
0.580.0

5583
3480.7
2282
484
1728168
4888478
343880
0.480.0

LEW

Total protein, g/l
Albumin, g/l
Globulin, calc g/l
Total bilirubin, mol/l
ALT, U/l
AST, U/l
ALP, U/l
PCV

12 weeks

(6)

LPK

(6)

LEW

6784
4083
2882
381
58818
135867
229853
0.580.0

24 weeks
(7)

LPK

5784
3282
2582
684
116897
2738144
239841
0.380.1

(6)

LEW

6789
3985
2584
2.480.7
1808142
2428103
200854
0.580.0

(8)

LPK

4789
2885
1984
580.8
49823
116853
139839
0.280.1

Adjusted
R2 value
0.60***
0.67***
0.53***
–0.71
0.23
0.21
0.84*
0.88***

Data represents mean 8 SD of combined male and female results. Globulin = Calculated (calc) from total protein and albumin
levels. Minimum number of animals in each group indicated by superscript associated with age/strain column. Significance of strain
effect: * p ≤ 0.05; *** p ≤ 0.001.

the kidney remained intact in LPK animals. The cut surface of the kidney had focal clusters of cysts that were
present in the cortex and medulla in the distribution of
medullary rays. At week 1, by light microscopy, focal areas of mild dilatation of proximal and distal tubules were
present, but cysts were absent (fig. 3a). By week 3, epithelial cell-lined cysts appeared throughout the cortex and
medulla (fig. 3b) and the size increased progressively
from 12 weeks (fig. 3c–f). Cysts were lined by cuboidal
and flattened cells and resembled epithelia from distal
nephron segments. Immunostaining for nephron-specific markers indicated that the majority of cysts stained
strongly and consistently for aquaporin-2 (fig. 4a, b). In
addition, some cells in the cysts stained positive for
Tamm-Horsfall protein (THP; fig. 4c, d) and occasionally medullary (but not cortical) cysts were positive for
aquaporin-1 (fig. 4e, f), indicating that cysts arose predominantly from the collecting ducts and to a lesser extent from the distal convoluted tubule, thick ascending or
thin descending limbs of the nephron.
Cyst Formation Is Associated with Tubule Cell
Proliferation/Dedifferentiation and Progressive
Tubulointerstitial Inflammation and Fibrosis
The number of PCNA-positive cortical tubule cells
was significantly greater in the LPK rats (fig. 5). Similarly, the number of vimentin-positive cortical tubule
cells was higher in affected LPK rats at all time points,
significantly increasing to week 12 (table 5). The number
of interstitial ED-1-positive cells was significantly higher
in the LPK animals at 6 and 12 weeks (p ^ 0.05; table 5).
Diffuse collagen deposition within the renal parenchyma
Cyst Development and CVS Disease in
PKD

was significantly different to the Lewis from week 12 onwards, increasing further at 24 weeks (p ^ 0.05, table 5).
Collagen deposition accompanied areas of tubular atrophy, glomerulosclerosis and/or areas dense in dedifferentiated epithelial cells. Use of blood pressure as a covariate
in the analysis indicated that collagen deposition in the
cortex and medulla was significantly associated with
blood pressure (p = 0.005, 0.018, respectively). Interstitial
myofibroblast accumulation (-SMA) was significantly
higher in the LPK animals relative to age-matched controls from week 6 (p ^ 0.05; table 5).
Hypertension Develops Early in LPK, Preceding
Cardiac Hypertrophy, and Is Abrogated by Ganglionic
Blockade
Tail cuff systolic blood pressures were elevated in LPK
rats from week 6 onwards (fig. 6a). Proportional heart
weight decreased in the Lewis and LPK between 3 and 6
weeks, but then increased in the LPK, becoming significantly greater than the Lewis from 12 weeks of age (fig. 6b).
Proportional LPK heart weights were significantly associated with blood pressure when entered as a covariate in
the model (p = 0.034, adjusted R 2 = 0.351). Hearts from
the LPK rats showed no cysts (fig. 6c), but histological examination showed LVH, multifocal muscle degeneration,
mild fibrosis, medial hypertrophy of cardiac vessels and
increased perivascular mast cell infiltration. Measurements of the left ventricular free wall confirmed LVH in
the LPK at 24 weeks of age when compared to Lewis
(fig. 6d). The interventricular septum was also significantly thicker in the LPK animals than aged matched
Lewis at 24 weeks of age (2,096 8 178 vs. 1,370 8 188 m,
Kidney Blood Press Res 2007;30:129–144
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a

b

c

d

Cyst diameter (mm)

3.0
2.5
2.0
1.5
1.0
0.5
0

f

1

3

6
Age (weeks)

12

24

e

Fig. 3. Cyst development in the LPK animals. a–e : Light micros-

copy of PAS sections of LPK kidneys from animals aged 1 week
(a), 3 weeks (b), 6 weeks (c), 12 weeks (d) and 24 weeks (e). Figures
illustrate absence of cysts in the first postnatal week (a) although
focal areas of dilated proximal and distal convoluted tubules were
present. At week 3 there was a rapid appearance of cysts through-

136

Kidney Blood Press Res 2007;30:129–144

out the cortex and medulla (b) and these cysts continued to increase in size as the animals aged (b–e). a–e Scale bar = 1.0 mm.
f Cyst diameter (mm) as measured using line morphometry. After
their appearance in week 3, the size of the cysts increased progressively from 12 weeks onwards (p ^ 0.05, adjusted R 2 = 0.916).
Data are means 8 SD. n values are presented in table 5.
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a

b

c

d

e

f

Fig. 4. Immunohistochemical staining of kidney sections for
aquaporin-2 (a, b, medulla), Tamm-Horsfall protein (c, d, medulla) and aquaporin-1 (e, f, cortex) in Lewis control (a, c, e) and
LPK (b, d, f) animals at week 3. Epithelial cells lining cysts (**)

extent Tamm-Horsfall protein (shown by arrows), but were rarely
positive for aquaporin-1. Results therefore indicate that cysts arise
predominantly from collecting ductules and the distal nephron.
Original magnification !200.

stained positive for aquaporin-2 (predominantly) and to a lesser
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Lewis

150

LPK

*

PCNA (cells/mm2)

120

*

90

*

60
30
0

3

6
Age (weeks)

a

12

24

Fig. 5. Cortical tubular epithelial cell (TEC) proliferation as eval-

uated by proliferating cell nuclear antigen (PCNA) staining.
a Number of positive cells expressed as cells per mm2. There were
significantly greater numbers of cells in the LPK relative to agematched Lewis controls at 3, 6 and 12 weeks of age. * Significant
difference between LPK and Lewis at that age, p ^ 0.05. There

was no significant difference between the Lewis at any age, but the
3- and 6-week-old LPK groups were significantly different to each
other, and all other LPK age groups (adjusted R 2 = 0.854, strain
effect p ^ 0.001). Data are means 8 SD; n values are in table 5.
b PCNA staining from a 3-week-old PKD. Original magnification
!200.

Table 5. Quantification of renal histopathological parameters in age-matched Lewis and LPK rats
Parameter

1 week
(6)

LEW

Vimentin, cora
ED-1/mm2 b
Collagen, cxa
Collagen, meda
-SMAc

3 weeks
(6)

LPK

0.380.2 1.480.5
9.380.9 14.085.6
0.080.1 0.280.2
0.180.1 0.180.1
5.081.2 3.681.1

(6)

LEW

6 weeks
(6)

LPK

0.180.1 3.080.4
5.181.1 14.082.6
0.080
0.0380.1
0.080.0 0.180.2
1.180.3 3.682.4

(6)

LEW

12 weeks
(6)

LPK

0.280.2 3.380.8
6.081.4 34.1820.3
0.180.1 0.2380.2
0.180.1 0.080
1.280.6 9.782.9

(7)

LEW

24 weeks
(7)

LPK

0.280.2 3.980.1
6.781.4 32.6822.7
0.2680.2 1.380.4
0.180.1 0.680.3
1.180.6 10.083.5

(6)

LEW

(10)

LPK

0.280.2 4.080.1
8.886.8 20.9813.8
0.480.2 2.580.5
0.180.1 1.880.5
0.880.3 12.282.3

Adjusted
R2 value
0.97***
0.44***
0.93*
0.89***
0.82**

Data represent mean 8 SD of combined male and female data.
Tubular vimentin staining and collagen deposition was scored with arbitrary units for the cortex (cx) or medulla (med).
b
Immunoreactivity for ED-1 was measured as number of immunoreactive cells in midcortical fields per mm2.
c
-Smooth muscle actin (-SMA) measured as % of cortical area occupied by positive staining for -SMA.
Minimum number of animals in each group indicated by superscript associated with age/strain column. Significance of strain effect: * p ≤ 0.05;
** p ≤ 0.01; *** p ≤ 0.001.
a

respectively, p ^ 0.05, adjusted R 2 = 0.720, strain effect
p ^ 0.001). There was no difference between strains for
right ventricular free wall thickness (data not shown).
In anaesthetised animals, ganglionic blockade had no
significant effect on the Lewis blood pressures (table 6)
but it significantly reduced both systolic and diastolic arterial pressures in the LPK, reducing systolic values to
pressures comparable to the Lewis, and reducing diastol138
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ic values to pressures less than the Lewis (in either the
presence or absence of hexamethonium; p ^ 0.05), indicating a greater relative drop in diastolic pressures. These
changes were reflected by the change in MAP (average
fall of 4% in the Lewis and 53% in the LPK). There was
no difference between pre- and post-hexamethonium
heart rates in either strain.
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LPK

Lewis

250

*

200

1.00

*
Heart weight (% BW)

Systolic BP (mm Hg)

*

*

150
100
50
0

*

0.75

0.50

0.25

0
3

a

*
*

6

12

16

3

24

Age (weeks)

6

b

12

16

24

Age (weeks)

*
LVFW thickness (µm)

3,000

2,000

1,000

0

c

Fig. 6. Hypertension and development of left ventricular hypertrophy. a Systolic blood pressure (BP; mm Hg, as measured by tail

cuff) and early and sustained presence of hypertension in the LPK
animals as compared to Lewis control from week 6 (p ^ 0.05, adjusted R 2 = 0.808, strain effect p ^.001). There was no significant
difference in blood pressure between the Lewis animals at any age
nor between the 6-, 12-, 16- and 24-week-old LPK. b Heart weight
data as a percentage of body weight (% BW) and significant difference between LPK and Lewis animals from 12 weeks of age
(p ^ 0.05, adjusted R 2 = 0.86, strain effect p ^ 0.001). There was
no difference between Lewis animals at 6, 12, 16 and 24 weeks of

Discussion

In this study we investigated the relationship between
cyst formation and indicators of renal function and cardiovascular disease in a new rat model of autosomal-recessive PKD. Our data demonstrate that cyst formation
preceded the development of hypertension, which in turn
heralded significant increases in serum urea and creatinine, increased cardiac mass and LVH, and eventual end
Cyst Development and CVS Disease in
PKD

d

3

6

12

16

24

Age (weeks)

age and there was no difference between the LPK animal at 6, 12,
16 and 24 weeks of age. c Transverse sections of rat hearts from a
24-week-old Lewis (left) and a 24-week-old LPK (right), and difference in size of the hearts. c Scale bar = 2 mm. d Thickness of
left ventricular free wall (LVFW; m) and the development of left
ventricular hypertrophy in the LPK animals at 24 weeks of age
(p ^ 0.05, adjusted R 2 = 0.836, strain effect p ^ 0.05). Age has a
significant effect on LVFW thickness in both strains (p ^ 0.001).
* Significant difference between LPK and Lewis at that age, p ^
0.05. Data are means 8 SD, n values are as presented in table 2.

stage renal disease. A key finding was evidence for a suppressed renin angiotensin system and heightened sympathetic drive during the established phases of the disease.
These finding therefore support the hypothesis that renal
structural abnormalities are a key event in the genesis of
hypertension and subsequent target organ disease in
PKD. Given that the most important mechanism of limiting renal disease progression is adequate blood pressure
control [21], an understanding of the temporal relationKidney Blood Press Res 2007;30:129–144
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Table 6. Blood pressure and heart rate

Lewis

response to ganglionic blockade

Systolic AP, mm Hg
Diastolic AP, mm Hg
Mean AP, mm Hg
Heart rate, bpm

LPK

pre-Hex

post-Hex

pre-Hex

post-Hex

11188
6489
8088
270839

10487
6587
7786
250829

178819
8884
11888
326836

84813*
4182*
5685*
292828

Adjusted
R2 value
0.88
0.90
0.92
0.37

Data represent mean 8 SD of combined data from animals of mixed sex aged 16
weeks. Arterial pressures (AP) were measured from rats under urethane anaesthesia preand post-treatment with the ganglionic blocker hexamethonium (Hex, subcutaneous, 3.3
mg/kg). Significant difference between pre- and post-treatment values: * p ≤ 0.05; n = 9.

ship between cystogenesis and hypertension is key for
providing effective therapeutic interventions.
The breeding analysis presented in this study confirms an autosomal recessive pattern of inheritance for
PKD in the LPK model. Autosomal-recessive PKD has
been shown to be due to mutations in the PKHD1 gene
[22], and indeed initial identification of the PKHD1 gene
arose from mapping of the pck rat model, allowing identification of the human ortholog [23]. The specific genetic mutation and likely role of genetic modifiers, which
are significant factors in human ARPKD [24], are not yet
known for the LPK model and form the basis for current
investigation by our group. Given that the functions and
mechanisms of the genes currently known to cause PKD
remain unclear, future identification of the responsible
gene in this model will provide valuable insight into the
pathogenesis of ARPKD in humans [8, 23].
The renal histopathology phenotype described in this
study further supports our finding of an autosomal-recessive mode of inheritance. Specifically, kidney enlargement was characterised by maintenance of the normal
reniform shape, and cysts were due to fusiform dilatation
predominantly of the collecting ducts and to a lesser extent other components of the distal nephron. Other autosomal-recessive forms of rodent PKD, such as the wpk,
also exhibit predominantly collecting duct-derived cysts
[10, 25] and in the spontaneously inherited cpk mouse
model of ARPKD, embryonic cystic lesions are localised
to the proximal tubule [26]. Likewise, in human ARPKD,
renal disease is characterised in utero by fusiform dilation of the collecting ducts [22, 23]. This is in contrast to
ADPKD, in both humans and murine models, where in
general cysts are thought to arise from the tubular portion of the nephron as well as the renal collecting system
[22].
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Our use of markers to identify cyst origin is substantiated by studies in humans and other rodent models where
aquaporins and THP have similarly been used to confirm
nephron segment localization of cysts in PKD [10, 19].
Indeed AQP1 and AQP2 belong to a group of proteins
which retain their segment-specific discriminatory differential expression even in end stage PKD [27]. With regard to the functional significance of staining for these
proteins in cystic epithelia of the LPK model, it has been
postulated that increased water permeability mediated by
aquaporins could contribute to the pathogenesis of cyst
formation by the facilitation of fluid secretion in to the
cystic lumen [27, 28]. Any potential role for THP, or uromodulin, however, is difficult to delineate, as the biological role of this mucoprotein is still unclear [28].
Temporal analysis of the renal histopathology indicated three distinct structural-functional phases characterised by: (1) a precursor cystic phase (week 1); (2) a cystic
phase (weeks 3–6) characterised by tubular epithelial cell
proliferation and dedifferentiation, interstitial inflammation with compensatory preservation of renal function, and (3) a cystic phase characterised by tubulointerstitial fibrosis correlating with progressive renal failure
(12 weeks). At week 1 precursor cystic lesions (namely focal dilations of proximal and distal tubules) were present.
By week 3, however, the medulla and cortex of the kidney
were grossly deranged with the presence of diffuse cystic
distal tubular dilatation only of predominantly collecting
ductules. Interestingly, in the presence of this gross distortion in renal structure, the serum creatinine was normal but blood pressure was significantly elevated by week
6. Cystic enlargement continued until week 24, but at a
much slower rate and preceded the development of the
other typical histological features of end-stage renal disease, including interstitial macrophage and myofibroPhillips et al.

blast accumulation, interstitial fibrosis and tubular cell
dedifferentiation.
Renal function deterioration in progressive chronic
kidney disease eventually leads to end stage renal failure
and death. Systemic hypertension and proteinuria, characteristics of the LPK model, are important progression
factors underlying all forms of chronic kidney disease
[21]. In addition to the described change in serum creatinine, laboratory abnormalities consistent with progression of renal dysfunction, including marked increases in serum urea, isosthenuria, decreased serum protein,
increased urinary protein to creatinine ratio and reduced
PCV were also evident after week 12. The rate of progression of renal insufficiency in the LPK model resembles
the time frame of morbidity for the ARPKD Wistar-chi
and pck (Crj:CD/SD) models [10, 25, 29, 30]. However,
unlike the Wistar-chi, wpk or pck ARPKD models, and
also the heterozygous Han:SPRD ADPKD model, the
LPK animals do not exhibit extra-renal pathology [8, 31,
32]. This is also in contrast to human ARPKD, which is
characterised by the combination of renal cystic disease,
congenital hepatic fibrosis, and the occasional occurrence of pancreatic fibrosis [22].
Of interest was the finding that LPK animals demonstrate gender dependent effects, with male animals showing higher overall elevations in serum urea and creatinine. This is consistent with human PKD and other animal models, where males undergo more rapid disease
progression and earlier onset of end stage renal disease
[33–35]. Studies in the Han:SPRD rat model suggest that
oestrogen has a protective effect that promotes the preservation of renal function through the regulation of mediators of growth and fibrosis [35].
Hypertension is a common finding in both ADPKD
and ARPKD in humans [36, 37] and is an important factor that not only accelerates renal failure but also drives
a spectrum of cardiovascular changes including LVH [6,
7, 38, 39]. In this study, blood pressure increased after
early cystogenesis yet prior to marked increases in indicators of renal function. In this regard, the LPK animals
show a strong similarity to human PKD. In ADPKD, 60%
of patients develop hypertension before renal function is
impaired [1] and in a recent retrospective study looking
at ARPKD, hypertension was present in 55% of patients,
with nearly all neonatal survivors requiring anti-hypertensive treatment [2]. As described, this is distinct to other rodent models of PKD which show no or only very mild
to moderate elevations in blood pressure [9–11, 35].
Several mechanisms have been proposed regarding
the pathogenesis of hypertension in PKD, including vol-

ume overload associated with an abnormal pressure-naturiesis response, activation of the RAAS associated with
renal cyst formation and induction of local tissue ischaemia, and increased sympathetic activity [40, 41]. With
regard to the RAAS, there is conflict in the literature and
it has been variably described as increased, decreased or
unchanged [3, 11, 40, 42, 43]. In ARPKD, it has been suggested that affected neonates are actually in a low renin
state [2, 10]. In this study, both PRA and Ang II levels
were low in LPK rats at 10–12 weeks of age. Markedly elevated systolic pressure and indicators of renal dysfunction at this age would suggest that extracellular fluid volume and total body sodium were likely to be increased
[44]. Given that sodium loading and increased arterial
pressure reduce renin secretion [45, 46], this may explain
the suppressed PRA. The reduced Ang II levels are likely
to be linked to the low PRA, as a number of studies have
shown that PRA and plasma Ang II are strongly correlated [47, 48] and respond similarly to interventions [48,
49]. However, suppressed renin at this time point does
not exclude a role for renin in the early pathogenesis of
hypertension. In one-kidney, one-clip Goldblatt hypertension, renin is elevated in the early phase and contributes to the early rise in arterial pressure but once sodium
retention occurs and arterial pressure rises the increase
in renin subsides and renin is usually suppressed in the
chronic phase [50, 51]. Similar observations have been
made in heart failure where, in animal models, renin rises early and is suppressed in the chronic state, and humans where renin is raised in de-compensated heart failure and tends to fall in chronic stable disease [52, 53].
Aldosterone levels were variable in the LPK, and while
on average not higher than control animals, did show a
positive correlation with serum creatinine. The basis of
this relationship is not known but a similar wide range of
aldosterone levels in the presence of reduced PRA have
been described previously in feline PKD [54]. Given renewed interest in the role of aldosterone in renal disease
progression [55], further studies to clarify the pathogenesis and therapeutic implications of this finding are warranted.
In humans a number of studies have provided strong
evidence for an important link between the observed
sympathetic hyperactivity and increased risk of cardiovascular morbidity in PKD [3, 4, 56]. Further, it has been
shown that muscle sympathetic nerve activity is increased
in hypertensive PKD patients regardless of renal function
[3]. In our study, sympathetic blockade was undertaken
to gain further information about the role of the SNS in
maintaining hypertension in PKD. The amount of hexa-
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methonium used was lower than used in other studies
(1/10th) [57, 58], and while it had no significant effect on
the normotensive Lewis controls, it had a pronounced effect on the hypertensive LPK. With the caveat that established hypertension induces vascular medial hypertrophy
and a vascular amplifier effect [59], these results nonetheless suggest that maintenance of hypertension in the LPK
rat is at least partly dependent on an intact SNS.
A number of mechanisms may drive sympathetic activation in PKD. It has been argued that renal ischaemia due
to structural changes stimulates inappropriate activation
of the renin-angiotensin system [3, 56], with high circulating levels of Ang II in turn directly stimulating central
sympathetic outflow via circumventricular organs that
lack a functional blood brain barrier [60, 61]. There is,
however, an increasing field of study to suggest that intrarenal ischaemia can modulate sympathetic efferent activity by direct stimulation of renal afferents [3, 5]. For example, in patients with end-stage renal failure, bilateral
renal nephrectomy corrects increased muscle sympathetic nerve activity concurrent with a reduction in blood
pressure [62], and in animal models of renal failure/injury, dorsal rhizotomy or renal denervation significantly
attenuates the degree of hypertension [63–65]. Given our
finding of low levels of PRA and circulating Ang II, the
LPK model will therefore be a useful tool for future evaluation of these pathophysiological interactions between the
renal, sympathetic and cardiovascular systems.
In conclusion, we have examined the temporal relationship between cardiac and renal disease progression

in ARPKD, demonstrating that renal structural abnormalities precede the development of hypertension, in
turn preceding marked changes in indices of renal dysfunction and cardiac hypertrophy. These data raise further hypotheses, including the role of the RAAS and SNS
in disease establishment and progression. It also raises
questions as to whether diminution of renal cyst formation with anti-proliferative agents such as mammalian
target of rapamycin inhibitors [66] can reduce cardiovascular morbidity by both slowing the development of hypertension as well as direct inhibitory effects on cardiac
structure. The key features of the LPK model including
the course of disease progression indicate it is a suitable
model in which to investigate the kidney-cardiovascular
axis and genetic pathogenesis of PKD.
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